<p>根据公司在最近向证券交易委员会提交的 13F 表格，Monument Capital Management 在第三季度将其在强生（NYSE:JNJ - 免费报告）股票中的持仓增加了 109.0%。该公司在此期间额外购买了 6,554 股后，持有 12,566 股强生的股票。Monument Capital Management 在强生的持股在最近一个季度末价值为 2,330,000 美元。</p>
<p>获取 <strong>强生</strong> 的提醒：</p>
<ul>
<li>降息使这三只收益 ETF 比以往更具吸引力</li>
</ul>
<p>其他大型投资者最近也对该公司的持仓进行了调整。Evolution Wealth Management Inc.在第二季度购买了强生的新股份，价值约为 27,000 美元。Semmax Financial Advisors Inc.在第二季度将其在强生的持股增加了 55.0%。Semmax Financial Advisors Inc.现在持有 203 股强生的股票，价值 31,000 美元，此前在上个季度额外购买了 72 股。GFG Capital LLC 在第二季度获得了强生的新持仓，价值为 35,000 美元。1248 Management LLC 在第一季度获得了强生的新股份，价值为 48,000 美元。最后，Vermillion &amp; White Wealth Management Group LLC 在第二季度将其在强生的持股增加了 66.4%。Vermillion &amp; White Wealth Management Group LLC 现在持有 376 股强生的股票，价值 57,000 美元，此前在上个季度额外购买了 150 股。机构投资者持有该公司 69.55% 的股票。</p>
<h2>分析师设定新目标价</h2>
<p>几位分析师对该公司发布了报告。Johnson Rice 在 10 月 22 日的报告中将强生的目标价设定为 190.00 美元，并给予该股票 “持有” 评级。巴克莱在 12 月 2 日的研究报告中将强生的目标价从 176.00 美元上调至 197.00 美元，并给予该股票 “等权重” 评级。华尔街 Zen 在 9 月 13 日的研究报告中将强生的评级从 “持有” 上调至 “买入”。大和资本市场在 10 月 20 日的研究报告中将强生的评级从 “中性” 上调至 “跑赢大盘”，并设定了 203.00 美元的目标价。最后，古根海姆在 12 月 5 日的报告中将强生的目标价从 206.00 美元上调至 227.00 美元，并给予该公司 “买入” 评级。四位研究分析师给予该股票 “强烈买入” 评级，十四位给予 “买入” 评级，九位给予 “持有” 评级。根据 MarketBeat.com，该公司的平均评级为 “适度买入”，共识目标价为 210.25 美元。</p>
<ul>
<li>辉瑞加大对减肥药物的投资</li>
</ul>
<p><strong>查看我们关于强生的最新研究报告</strong></p>
<h2>更多强生新闻</h2>
<p>以下是本周影响强生的主要新闻：</p>
<ul>
<li>积极情绪：欧盟批准 Tremfya 用于儿童斑块型银屑病，扩大了强生在免疫学领域的商业机会，使 Tremfya 成为首个获得任何儿童适应症批准的 IL-23 抑制剂——这可能带来收入增长。强生的 Tremfya 获得欧盟批准用于儿童斑块型银屑病</li>
<li>积极情绪：FDA 批准了 Rybrevant 的皮下制剂用于非小细胞肺癌，提高了患者便利性，并可能扩大与静脉注射相比的使用率；这增强了肿瘤学的增长前景。强生获得 FDA 批准推出非小细胞肺癌药物 Rybrevant 的皮下版本（修订版）</li>
<li>积极情绪：多篇分析师报告和模型投资组合继续将强生标记为 2026 年的高收益防御性股票——支持来自收益和保守股权投资者的需求。2026 年值得购买的前五只高收益标准普尔 500 股票，以获得可靠回报</li>
<li>中性情绪：Stifel Nicolaus 重申对强生的 “持有” 评级——提醒一些分析师尽管管道进展，但对短期上涨仍持谨慎态度。Stifel Nicolaus 重申对强生（JNJ）的持有评级</li>
<li>中性情绪：市场评论和收益预览强调了更强的第三季度业绩和近期的反弹/估值辩论——这些叙述有助于解释对该股票的兴趣，但不会立即改变基本面。以下是强生（JNJ）在第三季度飙升的原因</li>
<li>消极情绪：巴尔的摩陪审团裁定强生需支付约 15 亿美元的滑石粉/石棉间皮瘤案件赔偿——这是报告的最大单一原告滑石粉赔偿——造成法律责任风险、潜在的和解/上诉费用和头条波动。强生誓言上诉，因美国陪审团判其支付创纪录的 15 亿美元滑石癌赔偿</li>
<li>消极情绪：公司声明和多家媒体报道了该判决及持续的暴露（数以万计的滑石诉讼），这可能会影响情绪，提高法律储备或影响长期责任假设。超过 15 亿美元的巴尔的摩判决裁定强生对标志性婴儿爽身粉负责</li>
</ul>
<h2>强生股票上涨 1.1%</h2>
<ul>
<li>5 家医疗保健公司值得关注，因为行业轮动正在全面展开</li>
</ul>
<p>强生股票周四开盘价为 208.01 美元。该公司的 50 日移动平均线为 199.06 美元，200 日移动平均线为 180.31 美元。该公司的市值为 5011.4 亿美元，市盈率为 20.08，PEG 比率为 2.23，贝塔值为 0.36。强生的 12 个月低点为 140.68 美元，12 个月高点为 215.18 美元。该公司的速动比率为 0.80，流动比率为 1.07，债务与股本比率为 0.50。</p>
<p>强生（Johnson &amp; Johnson）（纽约证券交易所代码：JNJ - 获取免费报告）最近一次发布季度财报是在 8 月 30 日，报告显示该季度每股收益为 2.26 美元。强生的净利润率为 27.26%，股本回报率为 32.73%。该季度的营业收入为 240.2 亿美元。分析师平均预计强生在当前财政年度的每股收益将达到 10.58 美元。</p>
<h2>强生宣布分红</h2>
<p>该公司最近宣布了季度分红，已于 12 月 9 日支付。11 月 25 日的股东记录将获得每股 1.30 美元的分红。该分红的除息日为 11 月 25 日。这相当于年化 5.20 美元的分红和 2.5% 的分红收益率。强生的分红支付比率（DPR）为 50.19%。</p>
<h2>强生公司简介</h2>
<p>（免费报告）</p>
<p>强生是一家总部位于新泽西州新布伦瑞克的跨国医疗保健公司，开发、生产和销售广泛的产品，涵盖制药、医疗设备以及以前的消费者健康产品。该公司由约翰逊家族于 1886 年创立，已发展成为一个在全球多个国家开展业务和销售的全球医疗保健组织。</p>
<p>该公司的制药业务主要在其扬森研究与开发组织下运作，专注于免疫学、传染病、肿瘤学和神经科学等治疗领域的处方药。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票比强生更好</li>
<li>请勿删除，立即阅读</li>
<li>投资者警报：微型 “3 美元人工智能奇迹股票” 即将爆发</li>
<li>任何费用可以从资本利得税中扣除吗？</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
<li>忘掉人工智能，这将是下一个重大科技突破</li>
</ul>
<p><strong>想看看其他对 JNJ 感兴趣的对冲基金吗？</strong> 请访问 HoldingsChannel.com，获取强生（Johnson &amp; Johnson）（纽约证券交易所代码：JNJ - 免费报告）的最新 13F 文件和内部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在强生吗？</h2>
<p>在考虑强生之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而强生并不在名单上。</p>
<p>虽然强生目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

强生

<p>Monument Capital Management 在第三季度将其在强生的股份增加了 109%，目前持有 12,566 股，价值 233 万美元。这一举动是多家公司在强生进行更广泛投资活动的一部分。分析师对强生的评级褒贬不一，普遍目标价为 210.25 美元。近期的积极进展包括欧盟对 Tremfya 的批准和 FDA 对 Rybrevant 的许可，但法律挑战仍在继续，涉及 15 亿美元的滑石粉案件裁决</p>

<p>Monument Capital Management increased its position in shares of Johnson &amp; Johnson (NYSE:JNJ - Free Report) by 109.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities &amp; Exchange Commission. The firm owned 12,566 shares of the company's stock after acquiring an additional 6,554 shares during the period. Monument Capital Management's holdings in Johnson &amp; Johnson were worth $2,330,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>根据公司在最近向证券交易委员会提交的 13F 表格，Monument Capital Management 在第三季度将其在强生（NYSE:JNJ - 免费报告）股票中的持仓增加了 109.0%。该公司在此期间额外购买了 6,554 股后，持有 12,566 股强生的股票。Monument Capital Management 在强生的持股在最近一个季度末价值为 2,330,000 美元。</p>
</div><p>Get <strong>Johnson &amp; Johnson</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>强生</strong> 的提醒：</p>
</div><ul>
<li>Rate Cuts Make These 3 Income ETFs More Attractive Than Ever</li>
</ul>
<div class="lb-trans"><ul>
<li>降息使这三只收益 ETF 比以往更具吸引力</li>
</ul>
</div><p>Other large investors also recently made changes to their positions in the company. Evolution Wealth Management Inc. bought a new stake in Johnson &amp; Johnson during the second quarter worth approximately $27,000. Semmax Financial Advisors Inc. boosted its stake in shares of Johnson &amp; Johnson by 55.0% during the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company's stock worth $31,000 after acquiring an additional 72 shares in the last quarter. GFG Capital LLC acquired a new position in shares of Johnson &amp; Johnson in the 2nd quarter worth $35,000. 1248 Management LLC acquired a new stake in shares of Johnson &amp; Johnson during the first quarter worth $48,000. Finally, Vermillion &amp; White Wealth Management Group LLC lifted its holdings in shares of Johnson &amp; Johnson by 66.4% during the second quarter. Vermillion &amp; White Wealth Management Group LLC now owns 376 shares of the company's stock valued at $57,000 after purchasing an additional 150 shares during the last quarter. Institutional investors own 69.55% of the company's stock.</p>
<div class="lb-trans"><p>其他大型投资者最近也对该公司的持仓进行了调整。Evolution Wealth Management Inc.在第二季度购买了强生的新股份，价值约为 27,000 美元。Semmax Financial Advisors Inc.在第二季度将其在强生的持股增加了 55.0%。Semmax Financial Advisors Inc.现在持有 203 股强生的股票，价值 31,000 美元，此前在上个季度额外购买了 72 股。GFG Capital LLC 在第二季度获得了强生的新持仓，价值为 35,000 美元。1248 Management LLC 在第一季度获得了强生的新股份，价值为 48,000 美元。最后，Vermillion &amp; White Wealth Management Group LLC 在第二季度将其在强生的持股增加了 66.4%。Vermillion &amp; White Wealth Management Group LLC 现在持有 376 股强生的股票，价值 57,000 美元，此前在上个季度额外购买了 150 股。机构投资者持有该公司 69.55% 的股票。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>Several analysts have issued reports on the company. Johnson Rice set a $190.00 price objective on Johnson &amp; Johnson and gave the stock a &#34;hold&#34; rating in a report on Wednesday, October 22nd. Barclays lifted their target price on shares of Johnson &amp; Johnson from $176.00 to $197.00 and gave the stock an &#34;equal weight&#34; rating in a research report on Tuesday, December 2nd. Wall Street Zen upgraded shares of Johnson &amp; Johnson from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research report on Saturday, September 13th. Daiwa Capital Markets upgraded shares of Johnson &amp; Johnson from a &#34;neutral&#34; rating to an &#34;outperform&#34; rating and set a $203.00 price objective on the stock in a research report on Monday, October 20th. Finally, Guggenheim increased their target price on Johnson &amp; Johnson from $206.00 to $227.00 and gave the company a &#34;buy&#34; rating in a report on Friday, December 5th. Four research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $210.25.</p>
<div class="lb-trans"><p>几位分析师对该公司发布了报告。Johnson Rice 在 10 月 22 日的报告中将强生的目标价设定为 190.00 美元，并给予该股票 “持有” 评级。巴克莱在 12 月 2 日的研究报告中将强生的目标价从 176.00 美元上调至 197.00 美元，并给予该股票 “等权重” 评级。华尔街 Zen 在 9 月 13 日的研究报告中将强生的评级从 “持有” 上调至 “买入”。大和资本市场在 10 月 20 日的研究报告中将强生的评级从 “中性” 上调至 “跑赢大盘”，并设定了 203.00 美元的目标价。最后，古根海姆在 12 月 5 日的报告中将强生的目标价从 206.00 美元上调至 227.00 美元，并给予该公司 “买入” 评级。四位研究分析师给予该股票 “强烈买入” 评级，十四位给予 “买入” 评级，九位给予 “持有” 评级。根据 MarketBeat.com，该公司的平均评级为 “适度买入”，共识目标价为 210.25 美元。</p>
</div><ul>
<li>Pfizer Adds to Its Big Bet on Weight Loss Drugs</li>
</ul>
<div class="lb-trans"><ul>
<li>辉瑞加大对减肥药物的投资</li>
</ul>
</div><p><strong>View Our Latest Research Report on Johnson &amp; Johnson</strong></p>
<div class="lb-trans"><p><strong>查看我们关于强生的最新研究报告</strong></p>
</div><h2>More Johnson &amp; Johnson News</h2>
<div class="lb-trans"><h2>更多强生新闻</h2>
</div><p>Here are the key news stories impacting Johnson &amp; Johnson this week:</p>
<div class="lb-trans"><p>以下是本周影响强生的主要新闻：</p>
</div><ul>
<li>Positive Sentiment: EU approval for Tremfya in pediatric plaque psoriasis expands JNJ’s commercial opportunity in immunology and makes Tremfya the first IL‑23 inhibitor cleared for any pediatric indication — a potential revenue tailwind. JNJ's Tremfya Gets EU Approval for Pediatric Plaque Psoriasis</li>
<li>Positive Sentiment: FDA cleared a subcutaneous formulation of Rybrevant for NSCLC, improving patient convenience and potentially broadening uptake versus IV; this strengthens oncology growth prospects. J&amp;J Wins FDA Nod for Subcutaneous Version of NSCLC Drug Rybrevant (Revised)</li>
<li>Positive Sentiment: Multiple analyst pieces and model portfolios continue to flag JNJ as a high‑yield, defensive stock for 2026 — supporting demand from income and conservative equity investors. Top 5 High-Yield S&amp;P 500 Stocks to Buy for Reliable Returns in 2026</li>
<li>Neutral Sentiment: Stifel Nicolaus reiterated a Hold rating on JNJ — a reminder that some analysts remain cautious on near‑term upside despite pipeline progress. Stifel Nicolaus Reaffirms Their Hold Rating on Johnson &amp; Johnson (JNJ)</li>
<li>Neutral Sentiment: Market commentary and earnings previews highlight stronger Q3 results and recent rally/valuation debates — these narratives help explain interest in the stock but don’t change fundamentals immediately. Here’s Why Johnson &amp; Johnson (JNJ) Surged in Q3</li>
<li>Negative Sentiment: A Baltimore jury ordered J&amp;J to pay roughly $1.5B in a talc/asbestos mesothelioma case — the largest single‑plaintiff talc award reported — creating legal liability risk, potential settlement/appeal costs, and headline volatility. J&amp;J vows appeal after US jury hits it with record $1.5 billion talc cancer award</li>
<li>Negative Sentiment: Company statements and multiple outlets report the verdict and ongoing exposure (tens of thousands of talc suits), which could weigh on sentiment, raise legal reserves or influence long‑term liability assumptions. Over $1.5 Billion Baltimore Verdict Holds Johnson &amp; Johnson Liable Over Iconic Baby Powder</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：欧盟批准 Tremfya 用于儿童斑块型银屑病，扩大了强生在免疫学领域的商业机会，使 Tremfya 成为首个获得任何儿童适应症批准的 IL-23 抑制剂——这可能带来收入增长。强生的 Tremfya 获得欧盟批准用于儿童斑块型银屑病</li>
<li>积极情绪：FDA 批准了 Rybrevant 的皮下制剂用于非小细胞肺癌，提高了患者便利性，并可能扩大与静脉注射相比的使用率；这增强了肿瘤学的增长前景。强生获得 FDA 批准推出非小细胞肺癌药物 Rybrevant 的皮下版本（修订版）</li>
<li>积极情绪：多篇分析师报告和模型投资组合继续将强生标记为 2026 年的高收益防御性股票——支持来自收益和保守股权投资者的需求。2026 年值得购买的前五只高收益标准普尔 500 股票，以获得可靠回报</li>
<li>中性情绪：Stifel Nicolaus 重申对强生的 “持有” 评级——提醒一些分析师尽管管道进展，但对短期上涨仍持谨慎态度。Stifel Nicolaus 重申对强生（JNJ）的持有评级</li>
<li>中性情绪：市场评论和收益预览强调了更强的第三季度业绩和近期的反弹/估值辩论——这些叙述有助于解释对该股票的兴趣，但不会立即改变基本面。以下是强生（JNJ）在第三季度飙升的原因</li>
<li>消极情绪：巴尔的摩陪审团裁定强生需支付约 15 亿美元的滑石粉/石棉间皮瘤案件赔偿——这是报告的最大单一原告滑石粉赔偿——造成法律责任风险、潜在的和解/上诉费用和头条波动。强生誓言上诉，因美国陪审团判其支付创纪录的 15 亿美元滑石癌赔偿</li>
<li>消极情绪：公司声明和多家媒体报道了该判决及持续的暴露（数以万计的滑石诉讼），这可能会影响情绪，提高法律储备或影响长期责任假设。超过 15 亿美元的巴尔的摩判决裁定强生对标志性婴儿爽身粉负责</li>
</ul>
</div><h2>Johnson &amp; Johnson Stock Up 1.1%</h2>
<div class="lb-trans"><h2>强生股票上涨 1.1%</h2>
</div><ul>
<li>5 Healthcare Names to Watch as Sector Rotation Is in Full Swing</li>
</ul>
<div class="lb-trans"><ul>
<li>5 家医疗保健公司值得关注，因为行业轮动正在全面展开</li>
</ul>
</div><p>JNJ stock opened at $208.01 on Thursday. The company has a 50 day moving average of $199.06 and a two-hundred day moving average of $180.31. The company has a market cap of $501.14 billion, a price-to-earnings ratio of 20.08, a PEG ratio of 2.23 and a beta of 0.36. Johnson &amp; Johnson has a 12-month low of $140.68 and a 12-month high of $215.18. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50.</p>
<div class="lb-trans"><p>强生股票周四开盘价为 208.01 美元。该公司的 50 日移动平均线为 199.06 美元，200 日移动平均线为 180.31 美元。该公司的市值为 5011.4 亿美元，市盈率为 20.08，PEG 比率为 2.23，贝塔值为 0.36。强生的 12 个月低点为 140.68 美元，12 个月高点为 215.18 美元。该公司的速动比率为 0.80，流动比率为 1.07，债务与股本比率为 0.50。</p>
</div><p>Johnson &amp; Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson &amp; Johnson had a net margin of 27.26% and a return on equity of 32.73%. The business had revenue of $24.02 billion for the quarter. On average, equities analysts anticipate that Johnson &amp; Johnson will post 10.58 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>强生（Johnson &amp; Johnson）（纽约证券交易所代码：JNJ - 获取免费报告）最近一次发布季度财报是在 8 月 30 日，报告显示该季度每股收益为 2.26 美元。强生的净利润率为 27.26%，股本回报率为 32.73%。该季度的营业收入为 240.2 亿美元。分析师平均预计强生在当前财政年度的每股收益将达到 10.58 美元。</p>
</div><h2>Johnson &amp; Johnson Announces Dividend</h2>
<div class="lb-trans"><h2>强生宣布分红</h2>
</div><p>The company also recently declared a quarterly dividend, which was paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th were paid a dividend of $1.30 per share. The ex-dividend date of this dividend was Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.5%. Johnson &amp; Johnson's dividend payout ratio (DPR) is 50.19%.</p>
<div class="lb-trans"><p>该公司最近宣布了季度分红，已于 12 月 9 日支付。11 月 25 日的股东记录将获得每股 1.30 美元的分红。该分红的除息日为 11 月 25 日。这相当于年化 5.20 美元的分红和 2.5% 的分红收益率。强生的分红支付比率（DPR）为 50.19%。</p>
</div><h2>Johnson &amp; Johnson Company Profile</h2>
<div class="lb-trans"><h2>强生公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Johnson &amp; Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.</p>
<div class="lb-trans"><p>强生是一家总部位于新泽西州新布伦瑞克的跨国医疗保健公司，开发、生产和销售广泛的产品，涵盖制药、医疗设备以及以前的消费者健康产品。该公司由约翰逊家族于 1886 年创立，已发展成为一个在全球多个国家开展业务和销售的全球医疗保健组织。</p>
</div><p>The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.</p>
<div class="lb-trans"><p>该公司的制药业务主要在其扬森研究与开发组织下运作，专注于免疫学、传染病、肿瘤学和神经科学等治疗领域的处方药。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Johnson &amp; Johnson</li>
<li>Do not delete, read immediately</li>
<li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li>
<li>Can Any Expenses Be Deducted From Capital Gains Tax?</li>
<li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li>
<li>Forget AI, This Will Be the Next Big Tech Breakthrough</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比强生更好</li>
<li>请勿删除，立即阅读</li>
<li>投资者警报：微型 “3 美元人工智能奇迹股票” 即将爆发</li>
<li>任何费用可以从资本利得税中扣除吗？</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
<li>忘掉人工智能，这将是下一个重大科技突破</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding JNJ?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson &amp; Johnson (NYSE:JNJ - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 JNJ 感兴趣的对冲基金吗？</strong> 请访问 HoldingsChannel.com，获取强生（Johnson &amp; Johnson）（纽约证券交易所代码：JNJ - 免费报告）的最新 13F 文件和内部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=JNJ"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Johnson &amp; Johnson Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在强生吗？</h2>
</div><p>Before you consider Johnson &amp; Johnson, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑强生之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson &amp; Johnson wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而强生并不在名单上。</p>
</div><p>While Johnson &amp; Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然强生目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

强生 $JNJ 股票被 Monument Capital Management 收购